Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

Sun Yat-sen University logo

Sun Yat-sen University

Status and phase

Phase 2


Metastatic Castration-resistant Prostate Cancer


Drug: Pamiparib

Study type


Funder types




Details and patient eligibility


The purpose of this study is to assess the efficacy of a PARP inhibitor, Pamiparib, in metastatic castration-resistant prostate cancer patients with homologous recombination deficiency or BRCA 1 or 2 somatic/germline mutation.

Full description

This is a single arm, open-label, single center, phase II trial, assessing the efficacy of a PARP inhibitor, Pamiparib, in 50 progressing metastatic castration-resistant prostate cancer patients with at least one line of androgen deprivation therapy or chemotherapy at the metastatic setting, and homologous recombination deficiency or BRCA 1 or 2 somatic or germline mutation.


50 estimated patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  1. ≥18 years old, male

  2. Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma without neuroendocrine differentiation of the prostate. Mixed histology is accepted, except for small cell carcinoma.

  3. Have a deleterious mutation in BRCA1/2 , or HRD score ≥ 9.

  4. Eastern Cooperative Oncology Group (ECOG) performance status ≤1

  5. BPI<4

  6. Metastatic Castration-resistant Prostate Cancer (mCRPC): Presence of measurable target lesion according to RECIST criteria v1.1

  7. Male subject has been surgically or medically sterilized and has serum testosterone level ≤1.73nmol/L.

  8. Unsterilized male subject uses an acceptable method of contraception (defined as a barrier method with spermicide) to prevent pregnancy during the duration of the study and for 6 months after the last dose of Pamiparib.

  9. Experienced disease progression after having received at least 1 prior next-generation androgen receptor-targeted therapies, for metastatic castration-resistant disease.

  10. Capable of swallowing the whole capsule.

  11. Subjects must have normal organ and bone marrow function at baseline, as defined below:

    Hemoglobin ≥ 9.0 g/dL at least 28 days after transfusion . Absolute neutrophil count ≥ 1.5 × 10^9/L. Platelet count ≥ 100 × 10^9/L. Total bilirubin ≤ 1.5 × the upper limit of normal (ULN) specified. Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase/alanine aminotransferase (ALT) serum glutamic pyruvic transaminase) ≤ 3 × the specified ULN, unless liver metastases are present, in which case it must be ≤ 5 × ULN.

  12. Agree to sign informed consent form

  13. Agree not to participate in other interventional trials during this trial.

Exclusion criteria

Subjects should not enter the study if any of the following exclusion criteria are fulfilled:

  1. Acute toxicity (CTCAE > grade 2) due to prior cancer therapy.
  2. Received chemotherapy, endocrine therapy, biotherapy, radionuclide therapy, immunotherapy, experimental drugs, proprietary anticancer drugs or Chinese herbal medicines within 5 (if known) half-lives or 14 days(if unknown) prior to the first day of taking Pamiparib; For bisphosphonates or approved bone targeting therapy, Pamiparib must be administered at a steady dose for ≥28 days prior to the first day of taking Pamiparib.
  3. Received radiation therapy within 21 days.
  4. Prior treatment with any PARP inhibitor. Prior chemotherapy with mitoxantrone or platinum-based chemotherapy or cyclophosphamide. Prior treatment with sipuleucel-T or immune check point inhibitors are allowed.
  5. Subjects with major surgery within 2 weeks before starting study treatment. Subjects expected to receive major surgery during the trial.
  6. Active second malignancy, with the exception of curatively treated non-melanoma skin cancer, carcinoma in situ, or superficial bladder cancer
  7. Symptomatic and/or untreated central nervous system metastases
  8. Immunocompromised subjects, such as those with positive human immunodeficiency virus (HIV) serology.
  9. Subjects with known active hepatitis (e.g. hepatitis B or C).
  10. The subject has a serious cardiovascular disease. ( For example, but not limited to: uncontrolled arrhythmia, myocardial infarction)
  11. Concomitant use of strong CYP3A inducers or moderate CYP3A inducers . If half-lives is known, a 5 half-lives washout period is required before the start of Pamiparib therapy and a 2-week washout period is required when the half-lives is unknown.
  12. History of intolerance to Pamiparib capsule excipients
  13. Excluded by investigators

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

50 participants in 1 patient group

Experimental group
Tablets 20mg per os : 40 mg / bid every day in continuous. Patients will be treated with Pamiparib. Cycles are defined in 28-day periods. Disease response will be assessed every 8 weeks (RECIST 1.1). Safety will be assessed continuously.
Drug: Pamiparib

Trial contacts and locations



Central trial contact

Fangjian Zhou, M.D.; Yonghong Li, M.D.

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems